GSK announced positive headline results of a phase II trial for its mRNA seasonal influenza vaccine program. The trial studied a range of mRNA formulations in older and younger adults to evaluate vaccine candidates that could improve immune responses against influenza A and B strains, compared to the current standard of care. In both younger and older adults, pre-defined success criteria were met. Interim data suggest the vaccine candidates have an acceptable safety and reactogenicity profile for all mRNA formulations tested. GSK‘s Chief Scientific Officer, Tony Wood said: “This marks a significant advancement in our mRNA programme and these data support moving into late-stage development. Ultimately, our goal is to develop a new best-in-class vaccine to bring greater protection to people through the influenza season.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK reached confidential settlement with Dixon in Illinois Zantac case
- GSK says GSK3943104 did not meet Phase 2 study’s primary efficacy objective
- GSK presents full results from SWIFT-1 and SWIFT-2 Phase 3 trials
- GSK Reports Key Management Share Award
- GSK announces Phase III trial of Nucala met primary endpoint